Concord Biotech Ltd Share Price
As on 18 November 2025 at 23:51 IST
Concord Biotech Q1 FY26 Results:
Profit for the period declined 3.8% to ₹217.6 crores in Q1 FY26, from ₹227 crores in Q1 FY25. Total income for the quarter decreased 26.1% year-on-year to ₹44.05 crores from ₹59.59 crores.
About Concord Biotech Ltd
Concord Biotech Ltd is a research and development-driven biopharmaceutical company. It specializes in manufacturing Active Pharmaceutical Ingredients (APIs). The company operates in the biotechnology sector. Concord Biotech has established itself as a significant player in the industry. The company was founded in the year 2000, which makes it decades old. The headquarters of Concord Biotech Ltd is located in Ahmedabad, Gujarat. The company's main product includes APIs and finished formulations for various therapeutic areas. These products are essential for treating various medical conditions and are widely used in the industry. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-1.87%
Over 6 Months
-1.49%
Over 1 Year
-21.55%
Over 3 Years
59.34%
Concord Biotech Ltd Summary
Close ₹1,502.30
Open ₹1,513
High ₹1,513
Low ₹1,473.10
Volume 55,533
Net Turnover (in Cr) ₹8.32
52Wk High ₹2,451.70
52Wk Low ₹1,345
52Wk High / Low
1,345
2,451.70
Concord Biotech Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹15,716.49
EPS (TTM) 30.73
Book Value (BV) 174.47
Div. Yield 0.58 %
P/E (TTM) 48.86
Price/Book Value 8.61
Delivery % 47.04 %
Face Value 1
Key Ratios
PE Ratio 47.02
PB Ratio 9.67
EV to Sales 14.61
PEG Ratio 2.10
ROA 20.51
ROE 22.35
Debt-Equity -
Net Profit Margin 31.08
Operating Profit Margin 45.94
Concord Biotech Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|
| Total Revenue | 1,244.53 | 1,050.72 | 888.48 | 736.35 | 543.70 |
| Total Expenses | 748.66 | 641.53 | 568.42 | 495.19 | 330.21 |
| Profit Before Tax | 494.55 | 412.56 | 322.01 | 237.52 | 213.64 |
| Profit After Tax | 371.64 | 308.10 | 240.09 | 174.93 | 169.11 |
| Operating Profit After Depreciation | 496.40 | 411.75 | 324.56 | 246.64 | 214.19 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|
| Fixed Assets | 795.21 | 575.32 | 592.98 | 572.98 | 239.60 |
| Total Non Current Assets | 899.01 | 804.48 | 786.28 | 680.13 | 401.93 |
| Total Current Assets | 1,135.24 | 896.23 | 727.70 | 632.67 | 538.79 |
| Total Assets | 2,034.25 | 1,700.71 | 1,513.98 | 1,312.79 | 940.73 |
| Total Shareholder's Fund | 1,812.72 | 1,526.65 | 1,290 | 1,103.22 | 770.23 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 244.52 | 265.47 | 246 | 207.47 | 166.81 |
| Net Cash Used In Investing Activities | -159.99 | -154.61 | -157.95 | -111.79 | -195.44 |
| Net Cash Used In Financing Activities | -98.77 | -99.21 | -85.22 | -100.16 | 31.37 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,244.53 | 1,050.72 | 888.48 | 736.35 | 630.75 |
| Total Expenses | 748.66 | 641.53 | 568.42 | 495.19 | 317.58 |
| Profit Before Tax | 495.88 | 409.19 | 320.05 | 241.16 | 313.17 |
| Profit After Tax | 372.96 | 304.73 | 238.13 | 178.57 | 235.33 |
| Operating Profit After Depreciation | 496.40 | 411.75 | 324.56 | 246.64 | 313.83 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 795.21 | 575.32 | 592.98 | 572.98 | 546.22 |
| Total Non Current Assets | 898.94 | 803.08 | 786.95 | 680.79 | 575.70 |
| Total Current Assets | 1,135.24 | 896.23 | 727.70 | 632.67 | 607.15 |
| Total Assets | 2,034.18 | 1,699.32 | 1,514.65 | 1,313.46 | 1,182.84 |
| Total Shareholder's Fund | 1,812.65 | 1,525.25 | 1,291.98 | 1,107.16 | 999.67 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 244.52 | 265.47 | 246 | 207.47 | 166.81 |
| Net Cash Used In Investing Activities | -159.99 | -154.61 | -157.95 | -111.79 | -195.20 |
| Net Cash Used In Financing Activities | -98.77 | -99.21 | -85.22 | -100.16 | 31.12 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 247.06 | 203.99 | 429.88 | 244.22 | 310.18 |
| Total Expenses | 158.57 | 142.59 | 241.01 | 146.27 | 176.47 |
| Profit Before Tax | 85.68 | 58.73 | 183.53 | 101.15 | 130.33 |
| Profit After Tax | 63.06 | 44.06 | 140.39 | 75.92 | 95.74 |
| Operating Profit after Depreciation | 104.13 | 76.57 | 198.25 | 114.51 | 143.74 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 247.06 | 203.99 | 429.88 | 244.22 | 310.18 |
| Total Expenses | 156.52 | 142.59 | 239.46 | 146.27 | 173.51 |
| Profit Before Tax | 85.52 | 57.24 | 185.08 | 99.32 | 133.29 |
| Profit After Tax | 62.90 | 42.57 | 141.94 | 74.09 | 98.70 |
| Operating Profit after Depreciation | 103.97 | 75.08 | 199.80 | 112.68 | 146.70 |
Concord Biotech Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 1,479.27
S2 1,456.23
S3 1,439.37
Pivot 1,496.13
R1 1,519.17
R2 1,536.03
R3 1,559.07
Moving Average
20 SMA 1,466.21
50 SMA 1,554.60
100 SMA 1,659.21
200 SMA 1,706.87
Concord Biotech Ltd Corporate Actions
Concord Biotech Ltd
₹10.7/Share
Announcement Date 03 Sep 2025
Record Date 03 Sep 2025
Div Yield 1070%
Concord Biotech Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
Concord Biotech Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Quant Healthcare Fund | 3.14% |
| SBI Healthcare Opportunities Fund | 2.55% |
| DSP Healthcare Fund | 2.25% |
| Invesco India Multicap Fund | 0.96% |
| HSBC Small Cap Fund | 0.75% |
Concord Biotech Ltd News
Concord Biotech announces board meeting date
On 13 November 2025
08 Nov 2025, 09:56 am
Concord Biotech gains after successful EU-GMP inspection at Limbassi facility
Concord Biotech rose 3.30% to Rs 1,748.70 after the company's API manufacturing facility in Limbassi completed its first EU-GMP inspection.
21 Aug 2025, 03:25 pm
Concord Biotech's API unit in Limbassi concludes EU-GMP inspection
21 Aug 2025, 02:50 pm
Concord Biotech to conduct AGM
On 9 September 2025
14 Aug 2025, 02:48 pm
Concord Biotech to declare Quarterly Results
On 8 August 2025
04 Aug 2025, 12:03 pm
Concord Biotech Ltd Stock Analysis
- Annual revenue for Concord Biotech Ltd increased by 18.45% to ₹1,244.53 crore in FY 2025 from ₹1,050.72 crore in FY 2024.
- Annual Net Profit for Concord Biotech Ltd increased by 22.39% to ₹372.96 crore in FY 2025 from ₹304.73 crore in FY 2024.
- Promoter Shareholding in Concord Biotech Ltd remains unchanged by 0.00% in the most recent quarter, from 44.08% in June 2025 to 44.08% in September 2025.
- Concord Biotech Ltd delivered a 1-year return of -21.55% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
- Concord Biotech Ltd share price moved down by 0.11% from its previous close of INR ₹1,502.30. The latest Concord Biotech Ltd share price is INR ₹1,500.60.
- Concord Biotech Ltd share price today has been at a low of 1,493 and a high of 1,504.90. Over the past 52 weeks, the Concord Biotech Ltd share price has seen a low of 1,345 and a high of 2,451.70.
About Concord Biotech Ltd
Concord Biotech Ltd is a research and development-driven biopharmaceutical company. The company manufactures Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes. It also produces finished formulations to meet diverse healthcare needs. The company’s products cater to various therapeutic segments, including oncology and anthelmintics.
Operating in the biotechnology sector, Concord Biotech has established itself as a significant player in the industry. The company was founded in 2000, making it decades old. Over the years, Concord Biotech has evolved into a broad-spectrum solution provider. It now offers a wide range of products across diversified therapeutic segments.
The headquarters of Concord Biotech Ltd is located in Ahmedabad, Gujarat. This strategic location enables the company to manage its operations and logistics efficiently. It ensures timely delivery of products to customers across the globe. The company's promoters include Sudhir Vaid, with a 28.84% stake. A team of professional promoters manages the operations of the company-
While Concord Biotech is not currently the number one stock in its sector, however, it holds a significant position in the biotechnology industry. The company continues to expand its market share, positioning itself as a strong contender in the industry.
Concord Biotech Ltd is poised for continued growth and success in the biotechnology sector, driven by its innovative products and commitment to quality. The promoter shareholding in Concord Biotech is substantial, reflecting the confidence and commitment of its founders to the company’s long-term success.
The company focuses on creating value for its stakeholders. This includes customers and the communities it operates. Concord Biotech believes in building long-term relationships based on trust and mutual benefit.
Sustainability is at the core of Concord Biotech’s vision. The company is committed to reducing its environmental footprint through eco-friendly practices. This includes using renewable resources and promoting energy efficiency.
Innovation drives the company’s vision. Concord Biotech invests heavily in research and development to stay ahead of industry trends. The goal is to improve product quality and introduce new, innovative solutions continuously. The company believes that innovation is key to maintaining a competitive edge and meeting the evolving needs of the healthcare sector.
Customer satisfaction is a key aspect of the company’s vision. Concord Biotech aims to exceed customer expectations with its products and services. The company believes in understanding customer needs and providing tailored solutions. This customer-centric approach helps in building strong, long-term relationships.
The company also envisions expanding its global footprint. Concord Biotech aims to reach new markets and establish a solid international presence. Its vision includes becoming a preferred partner for pharmaceutical companies worldwide. The company plans to achieve this through strategic partnerships and collaborations.
Employee development is another important aspect of the vision. Concord Biotech aims to create a supportive and inclusive work environment. The company believes in nurturing talent and providing growth opportunities. This approach helps in building a motivated and skilled workforce.
The company also focuses on community engagement. Concord Biotech aims to contribute positively to the communities where it operates. This includes supporting local initiatives and promoting social responsibility. The company believes in giving back to society and making a difference.
Concord Biotech envisions leveraging technology to enhance its operations. The company aims to adopt advanced technologies to improve efficiency and productivity. This includes using automation and digital tools to streamline processes. The vision is to create an innovative and efficient manufacturing environment.
The company also aims to maintain high standards of corporate governance. Concord Biotech believes in transparency and ethical business practices. Its vision includes building trust with stakeholders through responsible management. The company aims to uphold integrity in all its operations.
Concord Biotech’s vision includes being a leader in quality assurance. The company aims to implement rigorous quality control measures. This ensures that all products meet the highest standards of safety and performance. The vision is to deliver reliable and high-quality products to customers.
The company also focuses on continuous improvement. Concord Biotech aims to review and enhance its processes regularly. The vision includes adopting best practices and staying updated with industry advancements. This helps in maintaining operational excellence.
Concord Biotech’s vision includes achieving financial growth and stability. The company aims to deliver consistent returns to its shareholders. Its vision includes strategic investments and prudent financial management. The company believes in creating long-term value for its stakeholders.
Operating in the biotechnology sector, Concord Biotech has established itself as a significant player in the industry. The company was founded in 2000, making it decades old. Over the years, Concord Biotech has evolved into a broad-spectrum solution provider. It now offers a wide range of products across diversified therapeutic segments.
The headquarters of Concord Biotech Ltd is located in Ahmedabad, Gujarat. This strategic location enables the company to manage its operations and logistics efficiently. It ensures timely delivery of products to customers across the globe. The company's promoters include Sudhir Vaid, with a 28.84% stake. A team of professional promoters manages the operations of the company-
- Ankur Vaid
- Ravi Kapoor
- Rajiv Ambrish Agarwal
- Bharti Khanna
While Concord Biotech is not currently the number one stock in its sector, however, it holds a significant position in the biotechnology industry. The company continues to expand its market share, positioning itself as a strong contender in the industry.
Concord Biotech Ltd is poised for continued growth and success in the biotechnology sector, driven by its innovative products and commitment to quality. The promoter shareholding in Concord Biotech is substantial, reflecting the confidence and commitment of its founders to the company’s long-term success.
Vision of Concord Biotech Limited
Concord Biotech Ltd envisions becoming a global leader in the biopharmaceutical industry. The company aims to achieve this through innovation and a solid commitment to quality. Its vision is to set new benchmarks in developing and manufacturing Active Pharmaceutical Ingredients (APIs) and finished formulations.The company focuses on creating value for its stakeholders. This includes customers and the communities it operates. Concord Biotech believes in building long-term relationships based on trust and mutual benefit.
Sustainability is at the core of Concord Biotech’s vision. The company is committed to reducing its environmental footprint through eco-friendly practices. This includes using renewable resources and promoting energy efficiency.
Innovation drives the company’s vision. Concord Biotech invests heavily in research and development to stay ahead of industry trends. The goal is to improve product quality and introduce new, innovative solutions continuously. The company believes that innovation is key to maintaining a competitive edge and meeting the evolving needs of the healthcare sector.
Customer satisfaction is a key aspect of the company’s vision. Concord Biotech aims to exceed customer expectations with its products and services. The company believes in understanding customer needs and providing tailored solutions. This customer-centric approach helps in building strong, long-term relationships.
The company also envisions expanding its global footprint. Concord Biotech aims to reach new markets and establish a solid international presence. Its vision includes becoming a preferred partner for pharmaceutical companies worldwide. The company plans to achieve this through strategic partnerships and collaborations.
Employee development is another important aspect of the vision. Concord Biotech aims to create a supportive and inclusive work environment. The company believes in nurturing talent and providing growth opportunities. This approach helps in building a motivated and skilled workforce.
The company also focuses on community engagement. Concord Biotech aims to contribute positively to the communities where it operates. This includes supporting local initiatives and promoting social responsibility. The company believes in giving back to society and making a difference.
Concord Biotech envisions leveraging technology to enhance its operations. The company aims to adopt advanced technologies to improve efficiency and productivity. This includes using automation and digital tools to streamline processes. The vision is to create an innovative and efficient manufacturing environment.
The company also aims to maintain high standards of corporate governance. Concord Biotech believes in transparency and ethical business practices. Its vision includes building trust with stakeholders through responsible management. The company aims to uphold integrity in all its operations.
Concord Biotech’s vision includes being a leader in quality assurance. The company aims to implement rigorous quality control measures. This ensures that all products meet the highest standards of safety and performance. The vision is to deliver reliable and high-quality products to customers.
The company also focuses on continuous improvement. Concord Biotech aims to review and enhance its processes regularly. The vision includes adopting best practices and staying updated with industry advancements. This helps in maintaining operational excellence.
Concord Biotech’s vision includes achieving financial growth and stability. The company aims to deliver consistent returns to its shareholders. Its vision includes strategic investments and prudent financial management. The company believes in creating long-term value for its stakeholders.
FAQ’s
What is the share price of Concord Biotech Ltd today?
Concord Biotech Ltd share price as on 18 Nov 2025 is ₹ 1500.6
What is the Market Cap of Concord Biotech Ltd?
The market cap of Concord Biotech Ltd stock is ₹15,716.49 Cr.
What is the PE Ratio of Concord Biotech Ltd?
The Price to Earnings (P/E) Ratio of Concord Biotech Ltd is 47.02
What is the PB Ratio of Concord Biotech Ltd?
The Price to Book (P/B) Ratio of Concord Biotech Ltd is 9.67
What is the 52 week high of Concord Biotech Ltd Share Price?
The 52 week high of Concord Biotech Ltd share price stands at ₹2,451.70
What is the 52 week low of Concord Biotech Ltd Share Price?
The 52 week low of Concord Biotech Ltd share price stands at ₹1,345
How can I buy shares of Concord Biotech Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Concord Biotech Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
